Európska únia - bulharčina - EMA (European Medicines Agency)

baxter holding b.v. - pemetrexed disodium heptahydrate - carcinoma, non-small-cell lung; mesothelioma - Антинеопластични средства - malignant pleural mesotheliomapemetrexed baxter in combination with cisplatin is indicated for the treatment of chemotherapy naïve patients with unresectable malignant pleural mesothelioma. non-small cell lung cancerpemetrexed baxter in combination with cisplatin is indicated for the first line treatment of patients with locally advanced or metastatic non-small cell lung cancer other than predominantly squamous cell histology (see section 5. pemetrexed baxter is indicated as monotherapy for the maintenance treatment of locally advanced or metastatic non-small cell lung cancer other than predominantly squamous cell histology in patients whose disease has not progressed immediately following platinum-based chemotherapy (see section 5. pemetrexed baxter is indicated as monotherapy for the second line treatment of patients with locally advanced or metastatic non-small cell lung cancer other than predominantly squamous cell histology (see section 5.

Európska únia - bulharčina - EMA (European Medicines Agency)

astrazeneca ab - tremelimumab - carcinoma, hepatocellular - Антинеопластични средства - imjudo in combination with durvalumab is indicated for the first line treatment of adults with advanced or unresectable hepatocellular carcinoma (hcc). imjudo in combination with durvalumab and platinum-based chemotherapy is indicated for the first-line treatment of adults with metastatic non-small cell lung cancer (nsclc) with no sensitising egfr mutations or alk positive mutations.

Európska únia - bulharčina - EMA (European Medicines Agency)

astrazeneca ab - tremelimumab - Карцином, недребноклетъчен белодроб - Антинеопластични средства - tremelimumab astrazeneca in combination with durvalumab and platinum-based chemotherapy is indicated for the first-line treatment of adults with metastatic non-small cell lung cancer (nsclc) with no sensitising egfr mutations or alk positive mutations.

Európska únia - bulharčina - EMA (European Medicines Agency)

novartis europharm limited - tislelizumab - esophageal squamous cell carcinoma - Антинеопластични средства - oesophageal squamous cell carcinoma (oscc) tevimbra as monotherapy is indicated for the treatment of adult patients with unresectable, locally advanced or metastatic oesophageal squamous cell carcinoma after prior platinum-based chemotherapy.

Európska únia - bulharčina - EMA (European Medicines Agency)

abbvie deutschland gmbh & co. kg - atogepant - Мигренозни разстройства - aquipta is indicated for prophylaxis of migraine in adults who have at least 4 migraine days per month.

Európska únia - bulharčina - EMA (European Medicines Agency)

abbvie deutschland gmbh & co. kg - epcoritamab - lymphoma, large b-cell, diffuse - Антинеопластични средства - tepkinly as monotherapy is indicated for the treatment of adult patients with relapsed or refractory diffuse large b-cell lymphoma (dlbcl) after two or more lines of systemic therapy.

Európska únia - bulharčina - EMA (European Medicines Agency)

merck europe b.v. - avelumab - Невроендокринни тумори - Други противоракови лекарства, моноклонални антитела - bavencio е показан като монотерапия за лечение на възрастни пациенти с метастазирал Меркел клетъчен карцином (МКК). bavencio в комбинация с акситиниб е предназначен за първа линия на лечение при възрастни пациенти с често почечно-клетъчен рак (pkr). bavencio is indicated as monotherapy for the first‑line maintenance treatment of adult patients with locally advanced or metastatic urothelial carcinoma (uc) who are progression-free following platinum‑based chemotherapy.

Európska únia - bulharčina - EMA (European Medicines Agency)

novartis europharm limited  - capmatinib dihydrochloride monohydrate - Карцином, недребноклетъчен белодроб - Антинеопластични средства - tabrecta as monotherapy is indicated for the treatment of adult patients with advanced non small cell lung cancer (nsclc) harbouring alterations leading to mesenchymal epithelial transition factor gene exon 14 (metex14) skipping, who require systemic therapy following prior treatment with immunotherapy and/or platinum based chemotherapy.